קלופידקסל 75

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

CLOPIDOGREL AS BESYLATE 75 MG

Available from:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC code:

B01AC04

Pharmaceutical form:

FILM COATED TABLETS

Administration route:

PER OS

Manufactured by:

PHARMATHEN S.A., GREECE

Therapeutic group:

CLOPIDOGREL

Therapeutic indications:

Clopidogrel is indicated for the prevention of atherothrombotic events as follows:• Recent MI, Recent stroke or Established peripheral arterial disease: Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. For patients with a history of recent myocardial infarction (MI), recent stroke or established peripheral arterial disease, Clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not) and other vascular death.• Acute coronary syndrome: For patients with acute coronary syndrome (Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) or ST segment elevation acute myocardial infarction), in combination with ASA in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG clopi

Authorization date:

2010-09-01